Prostate cancer Board decisions

The Board has remanded the case due to incomplete records and a need for further development, including obtaining additional medical records from various providers and requesting SSA disability determination records.

The Board has determined that the veteran's death was caused by metastatic bladder cancer due to or as a consequence of prostate cancer, which is service-connected. Therefore, service connection for the cause of the veteran's death is granted.

The Board has determined that the effective date for the veteran's TDIU is August 12, 2002.

The veteran's claim for an effective date prior to December 15, 2000 for the grant of service connection for prostate cancer was denied as he did not meet the requirements for a presumption-based award and his claim was filed after the regulatory addition of prostate cancer as a presumptive disease.

The veteran's claims for service connection and initial evaluations for his conditions are being remanded to obtain additional medical records, conduct further examinations, and consider the evidence.

The Board finds that the veteran's prostate cancer is not related to his service-connected prostatitis, and thus does not meet the criteria for service connection. The temporary total rating based on June 1997 treatment requiring convalescence is also denied.

The VA denied the veteran's claim for service connection for prostate cancer, attributing it to a lack of evidence linking the condition to his military service or exposure to herbicide agents.

The veteran's claim for service connection for residuals of a groin injury, including prostate cancer, is denied as there is no current disability due to the service injury and the prostate cancer is not related to service.

The veteran's prostate cancer is not related to his naval service and the claim for service connection is denied.

The Board has remanded the case due to the need for additional development, including verification of reserve service and obtaining relevant medical records.

The Board has determined that the veteran's chronic prostate cancer residuals warrant a 40 percent evaluation effective December 1, 2002. The earlier effective date claim is denied.

The veteran's claim for an initial rating in excess of 20 percent for residuals of prostate cancer and an earlier effective date for a grant of service connection is being remanded due to procedural defects.

The veteran was granted a 100 percent evaluation for the residuals of prostate cancer from February 29, 2000 to July 13, 2000.

The veteran's claim for a compensable evaluation for prostate cancer is remanded due to insufficient evidence of post-treatment residuals and the need for further examination. Service connection was granted, but no rating assigned.

The Board has determined that the veteran's type II diabetes mellitus and prostate cancer are not service-connected due to herbicide exposure in Vietnam. The duodenal ulcer disease claim is granted with restoration of a 20 percent rating.

The Board has determined that additional development is necessary prior to completion of its appellate review due to missing VA medical records from before 2001 and relevant to the claimed disabilities on appeal.

The Board denied the veteran's claims of service connection for benign prostatic hypertrophy and an initial rating in excess of 20 percent for diabetes mellitus, finding no evidence linking these conditions to his active duty service or presumed exposure to herbicides.

The Board has granted a 40 percent disability rating for the veteran's prostate cancer, effective June 17, 2004. The veteran previously had a 20 percent rating prior to that date.

The Board has granted a 10 percent evaluation for the service-connected chronic prostatitis and has determined that prostate cancer is secondary to the service-connected chronic prostatitis.

The veteran is granted nonservice-connected disability pension benefits with special monthly pension by reason of the need for aid and attendance due to multiple orthopedic problems, visual impairment, urinary tract infections, kidney stones, and prostate cancer.